Astrazeneca’s Appeal on Cancer Drug Rejected
Drug companies have always fought long battles when it came to securing a patent in India. It has never been an easy ride to seek patent protection on drugs in India. For instance, the revocation of Swiss Company, Roche’s six year old patent on hepatitis C drug Pegasys. Even if the companies did manage to get a patent for their drug in India, more often than not, they do not enjoy patent protection for complete 20 years. For instance, the issuance of compulsory license on, German Pharma Company, Bayer’s cancer drug Nexavar.
Section 3 (d) of the Indian Patent Act has always been a hurdle for these drug companies. Time and again, big global pharma companies have been denied patents because of this provision which aims at preventing ever-greening of patents. Many drug companies tweak existing patents and seek a fresh period of protection. The law requires the drugs to establish significant efficacy when compared to existing products in the market to qualify for a fresh patent……
Contributed by Sneha Ashok